Wearable Devices Ltd. — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone Q4 filing; quarterly results are not provided in the filing text. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Business context
Wearable Devices develops a wrist-worn, non-invasive neural interface that uses subtle finger movements to control digital devices. The company describes itself as transitioning from R&D toward commercialization, with early revenue from Mudra Inspire development kits and B2B pilot activity. Its first consumer product, the Mudra Band for Apple Watch, was still in final testing/manufacturing at the filing date. The company reported 126 B2B development-kit customers and 92 customer use-cases in 2022; it had not signed a technology licensing agreement as of March 20, 2023.
Key financial metrics
| U.S. dollars, unless noted | FY2022 | FY2021 |
|---|---|---|
| Revenue | $45,000 | $142,000 |
| Cost of materials | $10,000 | $10,000 |
| Operating loss | $6.458 million | $2.669 million |
| Net and comprehensive loss | $6.496 million | $2.614 million |
| Net loss per share | $0.53 | $0.27 |
| Cash used in operating activities | $5.714 million | $2.103 million |
| Cash used in investing activities | $66,000 | $36,000 |
| Cash provided by financing activities | $14.879 million | $2.938 million |
| Cash and cash equivalents at year-end | $10.373 million | $1.274 million |
| Total assets | $11.224 million | $1.445 million |
| Total liabilities | $1.244 million | $638,000 |
| Accumulated deficit | $13.409 million | $6.913 million |
Revenue was entirely from Mudra Inspire kit sales in 2022. The filing attributes the 68% revenue decline mainly to a $84,000 pilot transaction included in 2021 revenue. Cost of materials was unchanged. The increase in losses reflected higher R&D, sales and marketing, G&A, and IPO expenses. Gross profit was approximately $35,000, or about 78% of revenue, calculated from reported revenue and materials cost; this small product-sales base is not indicative of established operating margins.
Liquidity improved following the September 2022 IPO. The company reported approximately $13.3 million in net proceeds after underwriting discounts, commissions, and other offering costs. It had 15,049,720 ordinary shares outstanding at December 31, 2022. The $800,000 senior secured credit facility drawn during 2022 was repaid upon the IPO; no financial borrowing balance is shown at year-end. Balance-sheet lease liabilities totaled $162,000. Current assets were $10.976 million versus current liabilities of $1.150 million.
Material changes versus the prior comparable period
- Revenue fell by $97,000, or 68%, while net loss rose by $3.882 million, or 149%.
- R&D expense increased 61% to $2.271 million; sales and marketing expense increased 106% to $1.370 million; and G&A expense increased 210% to $1.948 million. IPO expenses were $904,000, compared with $97,000 in 2021.
- Operating cash outflow increased to $5.714 million from $2.103 million. Financing cash inflow, principally from the IPO, lifted year-end cash by $9.099 million.
- The 2021 audited statements included an explanatory paragraph raising substantial doubt about going concern. The 2022 auditor’s opinion was unmodified but emphasized recurring losses and negative operating cash flows; management prepared the statements on a going-concern basis.
Outlook, risks, contingencies and unusual items
- Management said existing cash, including IPO proceeds, was expected to fund working capital and capital expenditure requirements through June 2024. The audited financial statement note separately says management believed cash would be sufficient for at least one year from the March 21, 2023 approval date. The company expects continuing substantial losses and may need additional financing; availability and terms are uncertain.
- The company expected to begin shipping Mudra Band pre-orders in Q3 2023. The disclosed pre-order price was $179 and suggested retail price $249. Mudra XR was planned for launch in Q4 2024. These are forward-looking expectations, not reported outcomes.
- Commercialization remains unproven: the company had no B2B license agreements as of March 20, 2023, and estimated a three-to-five-year customer engagement period before licensing. Product launch, customer adoption, production scale, and profitability remain uncertain.
- Key risks include dependence on single-source manufacturers and suppliers, long B2B sales cycles, competition and alternative input technologies, privacy and cybersecurity exposure involving sensitive neural and movement data, intellectual property protection, and political or security conditions in Israel. COVID-19 had slowed B2B engagement and affected component lead times, manufacturing cycles, and shipping.
- IIA grants carried contingent royalties of 3%–3.5% on relevant product sales, up to grant amounts plus interest; the reported contingent principal obligation was approximately $1.8 million. Approval to move some manufacturing abroad was received in December 2022, but overseas production may increase royalty rates and the repayment ceiling. A January 2023 IIA program approved approximately $900,000 of manufacturing-process funding, with IIA financing 60%.
- Nasdaq notified the company in November 2022 that its share price had failed the $1.00 minimum bid requirement; the stated compliance deadline was May 22, 2023. The company said it might consider a reverse stock split. IPO warrants’ exercise price reset from $4.00 to $2.00 in December 2022; 169,125 additional shares were issued to April 2021 investors in February 2023 following the adjustment.
- The company reported disclosure controls effective at December 31, 2022 and said it remediated 2021 material weaknesses related to U.S. GAAP expertise. It was still documenting and strengthening internal financial-reporting controls; the filing includes no management assessment or auditor attestation of ICFR. No material legal proceedings were reported for the period. No cash dividends are anticipated in the foreseeable future.
Important facts for investors to verify
- Whether Mudra Band shipments began as planned, and actual production volume, returns, customer demand, and unit economics.
- Whether B2B pilots progress to signed, revenue-generating license agreements, and the timing and economics of any such agreements.
- Cash burn, remaining runway, subsequent financing needs, and the company’s ability to meet its stated outlook without dilutive financing.
- Current Nasdaq listing compliance and any reverse split or other action taken to address the minimum bid-price deficiency.
- Potential dilution from outstanding warrants, employee options, and investor price-protection provisions, alongside the final warrant exercise terms.
- IIA royalty and manufacturing obligations, including the effect of production outside Israel and the terms and receipt of approved grant funding.